KANEKA KanCapA Selected by Global Pharmaceutical Companies

Kaneka Corporation (Osaka, Japan; President: Kimikazu Sugawara) is pleased to announce that its new Protein A Chromatography Resin (KANEKA KanCapA), sold as a purification media for therapeutic antibodies , has been officially selected for scale up and clinical development studies by several global pharmaceutical companies’.

KANEKA KanCapA which combines high binding capacity at high flow rates with alkaline resistance was officially launched in Oct. 2012. A number of customers have already evaluated KANEKA KanCapA and have confirmed its high performance characteristics, safety and ease of use. Several investigational MAb drugs have been already produced using KANEKA KanCapA and one customer will start clinical development studies soon.

Until the launch of KANEKA KanCapA the Protein A Chromatography Resin market had been dominated by only a few companies. The introduction of KANEKA KanCapA to the marketplace offers customers a high performance, safe and easy to use alternative. Our goal is to reach sales of 10 billion Japanese Yen by 2018, and to support customers’ cost reduction initiatives in biopharmaceutical production.

To meet our goals we will expand our current production facilities to meet predicted commercial demands and establish a reliable production system to fully support and satisfy our customers’ needs.